OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
100,100
+15,600 (18.46%)
Sep 19, 2025, 3:30 PM KST
18.46%
Market Cap2.01T
Revenue (ttm)7.54B
Net Income (ttm)-45.14B
Shares Out20.11M
EPS (ttm)-2,478.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,134,895
Average Volume1,743,658
Open85,500
Previous Close84,500
Day's Range85,300 - 107,500
52-Week Range13,380 - 107,500
Beta0.58
RSI73.43
Earnings DateAug 14, 2025

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2024, OliX Pharmaceuticals's revenue was 5.68 billion, a decrease of -66.73% compared to the previous year's 17.06 billion. Losses were -40.66 billion, 112.9% more than in 2023.

Financial Statements

News

There is no news available yet.